AMBOSS secures €240M to broaden digital tools for global clinicians
Berlin-based healthtech company AMBOSS raises significant funding to expand its reach across new markets and support medical professionals worldwide.
Elena Whitmore 
Digital health platform AMBOSS, headquartered in Germany, has announced the closing of a €240 million funding round, aimed at expanding its international footprint and diversifying its offerings beyond physicians. The company intends to use the new capital to strengthen its technology infrastructure, pursue strategic acquisitions, and extend its services to include nurses and other healthcare workers.
Strategic investments to boost international reach
The investment round was led by KIRKBI, M&G Investments, and Lightrock, with continued support from existing investor Partech. The company’s leadership emphasized the strategic nature of the partnerships, highlighting that most of the new investors operate evergreen funds and are committed to long-term collaboration. According to Benedikt Hochkirchen, Co-founder and Co-CEO of AMBOSS, the goal is to work with partners who are “committed to our long-term vision and very flexible in the investment duration.”
The funding arrives following AMBOSS’ acquisition of Novaheal, a startup serving the nursing field, and NEJM Knowledge+, a U.S.-based board exam preparation tool for medical residents. These acquisitions reflect the company’s broader ambition to support clinical decision-making across the healthcare spectrum.
A growing global user base
Founded in 2012 by a team of physicians, AMBOSS has grown into a widely used platform among medical professionals, combining up-to-date clinical knowledge with AI-supported tools to enhance decision-making at the point of care. The platform now serves over 1 million users in 180 countries. Its global workforce includes more than 500 employees representing 50+ nationalities, with over 150 of them being physicians.
“Technology will not replace healthcare professionals, but those who embrace it will lead the way,” said Dr. Madjid Salimi, Co-founder and Co-CEO, underlining the role of AI in supporting—not replacing—clinical expertise.
Utilization across Germany and the U.S.
Data shared by AMBOSS highlights its impact in both Germany and the United States. In Germany, one out of every two inpatient treatments is reportedly managed by a physician who uses AMBOSS. In the U.S., most medical students turn to the platform for exam preparation, and approximately 25% of first-year residents rely on it to guide patient care.
Long-term vision and product development
The company’s approach is centered on collaboration between medical professionals and technology developers, aiming to provide real-time access to accurate and actionable medical knowledge. The funds will enable further development of the platform’s clinical tools and content, supporting practitioners across various stages of their careers.
Peter Bason, Head of Private Capital at KIRKBI, noted the company's progress in the U.S. and its consistent focus on innovation. He described AMBOSS as a tool that supports decision-making “at every stage” for healthcare workers and students alike.
With this substantial backing, AMBOSS plans to continue evolving its platform as a comprehensive digital co-pilot for medical professionals worldwide.
